Drugs / Intanza
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Intanza | — | 2018-08-03 | europa.eu ↗ |
| Approved | EU (EMA) | Intanza | — | 2009-02-24 | europa.eu ↗ |
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02960815 | Nov 2016 → Jun 2017 | — | University of Lausanne Hospitals | Completed | No outcome recorded |
| Phase 2 | NCT00776438 | Sep 2007 → Feb 2009 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01967368 | Oct 2013 → May 2014 | influenza | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT01665807 | Sep → Dec 2012 | influenza | Brenda Coleman | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01180699 | Oct 2010 → Aug 2012 | — | University of Alberta | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT01368796 Comparator | Jul → Dec 2011 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT01224613 Comparator | Nov 2010 → Jan 2011 | influenza | Dalhousie University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intanza | “Intanza® 9 μg (Sanofi Pasteur), a trivalent split-virion vaccine administered by intradermal (ID) injection” PMID 25483667 ↗ 2014 |
| Modality | Vaccine | “standard influenza vaccine” NCT01180699 ↗ |
| Route | Other | “It is given into the skin over the upper arm at a dose of 0.1 mL.” NCT01368796 ↗ |